

The HA Drug Advisory Committee (DAC), comprising doctors, clinical pharmacologists and pharmacists, systematically appraises new drugs every three months. DAC is supported by expert panels which provide specialist views on the selection of drugs for individual specialties.

Drug Advisory Committee Oct 2019 Meeting Outcome

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection ¹
1	Avelumab	Bavencio	Malignant disease and immunosuppression	Rejected	Insufficient evidence to demonstrate significant clinical outcome benefits
2	Baloxavir	Xofluza	Infections	Pending	Pending further information
3	Brentuximab Vedotin	Adcetris	Malignant disease and immunosuppression	Approved in principle	
4	Brivaracetam	Briviact	Central nervous system	Approved	
5	Cladribine	Mavenclad	Malignant disease and immunosuppression	Rejected	Alternative(s) available in HADF with comparable benefits
6	Cyclosporine	Restasis	Eye	Approved	
7	Daratumumab	Darzalex	Malignant disease and immunosuppression	Pending	Pending further information
8	Denosumab	Xgeva	Endocrine system	Approved	
9	Dupilumab	Dupixent	Skin	Pending	Pending further information
10	Durvalumab	Imfinzi	Malignant disease and immunosuppression	Approved	
11	Emicizumab	Hemlibra	Cardiovascular system	Approved	
12	Guselkumab	Tremfya	Skin	Approved	
13	Ketoanalogue	Ketosteril	Nutrition and blood	Rejected	This is a nutritional supplement
14	Levosimendan	Simdax	Cardiovascular system	Approved	
15	Mirabegron	Betmiga	Obstetrics, gynaecology, and urinary-tract disorders	Approved	
16	Niraparib	Zejula	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
17	Pertuzumab	Perjeta	Malignant disease and immunosuppression	Rejected	Insufficient evidence to demonstrate significant clinical outcome benefits
18	Racecadotril	Hidrasec	Gastro-intestinal system	Approved	
19	Ribociclib	Kisqali	Malignant disease and immunosuppression	Rejected	Alternative(s) available in HADF with comparable benefits
20	Rifapentine	Priftin	Infections	Approved	

21	Ticagrelor	Brilinta	Cardiovascular system	pending	Pending further information
22	Tolvaptan	Jinarc	Endocrine system	Approved	
23	Tolvaptan	Samsca	Endocrine system	Approved	

¹ The evaluation embraces the principles of safety, efficacy and cost-effectiveness and takes into account other relevant factors, including international recommendations and practices, advance in technology, disease state, patient compliance, quality of life, actual experience in the use of drugs as well as views of professionals and patients groups.